Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio, Inc. (NYSE: IBIO) has partially adjourned its 2021 Annual Meeting of Shareholders to allow further voting on two key proposals: a Reverse Stock Split and a Change in Authorized Shares. As of now, shareholders are supporting these proposals by a 2-to-1 margin. The Annual Meeting will reconvene on January 31, 2022, at 9:00 a.m. Eastern time. The company encourages those who have not yet voted or who voted against the proposals to reconsider their stance.
iBio, a developer of biopharmaceuticals, announced that its 2021 Annual Shareholders meeting is set for December 22, 2021, at 9:00 AM EST. The meeting will address two critical proposals: a reverse stock split and an increase in authorized shares. Currently, 64% and 67% of shareholders have voted in favor, but additional votes are necessary for approval. iBio encourages shareholders who have not yet voted to participate. The company is recognized for its sustainable, plant-based FastPharming Manufacturing System, aimed at developing treatments for various diseases.
iBio announced the partial adjournment of its annual meeting of stockholders to December 22, 2021, with over 60% of shares voting in favor of a reverse stock split and authorized share decrease. Proposals 4 and 5 received 64% and 67% support, respectively. Both Glass Lewis and ISS recommended approving these measures. The Company aims to secure the requisite majority from all outstanding shares to facilitate its growth strategy while encouraging additional votes from shareholders who have not yet voted.
iBio, Inc. (NYSEA:IBIO) announced an update on its COVID-19 vaccine, IBIO-202, in response to the Omicron variant. Classified by WHO as a Variant of Concern, the Omicron variant has numerous mutations in the spike protein, which traditional vaccines target. iBio’s strategy focuses on the nucleocapsid protein, believed to be more conserved and effective against variants. The company expects feedback from the U.S. FDA by January regarding its pre-IND application for IBIO-202.
iBio, a developer of biopharmaceuticals, reported Q1 2022 revenues of approximately $211,000, down 49% year-over-year. The company has advanced its oncology initiatives with new collaborations and has initiated research on anti-fibrotic treatments. iBio has also begun implementing new vaccine delivery technologies and acquired a cGMP manufacturing facility. Despite an increased net loss of $8.9 million, iBio retains $82.3 million in cash reserves, allowing operations to continue through Q3 2023. The company aims for growth throughout FY2022.
iBio, Inc. (IBIO) announced a research collaboration with UT Southwestern to investigate the anti-cancer effects of its IBIO-100 program in solid tumors. The focus will be on cancer-associated fibroblasts (CAFs) and the molecule endostatin E4, which may enhance chemotherapy and immunotherapy outcomes. Tom Isett, iBio's CEO, expressed enthusiasm about the partnership, while Chief Scientific Officer Martin Brenner highlighted the importance of targeting fibrosis for better cancer treatment responses. The research aims to explore how to normalize fibrotic environments without destroying CAFs.
iBio, Inc. (NYSEA:IBIO) will report its fiscal 2022 first quarter financial results after market close on November 15, 2021. The company, known for its sustainable, plant-based FastPharming Manufacturing System, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss these results and provide a corporate update. Investors can access the live and archived webcast on the company's website. iBio focuses on developing biopharmaceuticals for treating cancers, fibrotic conditions, and infectious diseases.
iBio, Inc. (NYSEA:IBIO) has acquired full ownership of its CDMO subsidiary and U.S. manufacturing rights for its FastPharming System, reducing carrying costs by approximately 67%. The transaction, valued at $28.75 million, was financed through cash and warrants for stock. This move is expected to enhance strategic flexibility and operational growth in Texas, while iBio anticipates sustaining its operations with its current cash position through Q1 2023.
iBio, Inc. (NYSEA:IBIO) urges stockholders to vote “FOR” all proposals in their proxy statement ahead of the December 9, 2021 Annual Meeting. The proposals include amendments to the Company’s Articles of Incorporation requiring majority approval. Stockholders with shares as of October 15, 2021, are eligible to vote. CEO Tom Isett highlights the importance of shareholder participation for strategic growth. A new Q&A page has been created to facilitate communication. Stockholders can access their voting instructions via proxy cards or by contacting Okapi Partners for assistance.
iBio, a developer of biopharmaceuticals, announced its fiscal Q4 and annual results for 2021. Revenues reached $2.4 million, a 50% increase year-over-year, though Q4 revenue dropped to $0.5 million. Key developments include a partnership with RubrYc for an anti-CD25 antibody, expansion into oncology, and progress on the COVID-19 vaccine, IBIO-202. The company's consolidated net loss widened to $23.2 million, influenced by $10.2 million from a legal settlement. iBio's cash position is robust, at $97 million, allowing funding through Q1 2023.